Form4insider filings, from the source

SEC Form 4 · accession 0001225208-19-002353

JOHNSON & JOHNSON · JNJ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jennifer L Taubert
Officer — EVP, WW Chair, Pharmaceuticals
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 9:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000200406

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Feb 8, 2019M8,529$0.00A72,205D
Common StockF2Feb 8, 2019F3,565$132.00D68,640D
Common StockF3Feb 11, 2019M9,748$0.00A78,388D
Common StockF4Feb 11, 2019A1,599$0.00A79,987D
Common StockF5Feb 11, 2019F6,236$131.94D73,751D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Share UnitsF1—Feb 8, 2019M8,529DFeb 8, 2019—Common Stock8,5290D
Employee Stock Options (Right to Buy)F6$131.94Feb 11, 2019A67,397AFeb 11, 2022Feb 11, 2029Common Stock67,39767,397D
Performance Share UnitsF3—Feb 11, 2019M9,748DFeb 8, 2019—Common Stock9,7480D
Restricted Share UnitsF7—Feb 11, 2019A3,297AFeb 11, 2022—Common Stock3,2973,297D

Explanation of responses

Remarks

poataubert.txt